You are not logged in.

Management of advanced neuroendocrine tumors with hepatic metastasis

Khasraw, Mustafa, Gill, Anthony, Harrington, Tim, Pavlakis, Nick and Modlin, Irvin 2009, Management of advanced neuroendocrine tumors with hepatic metastasis, Journal of clinical gastroenterology, vol. 43, no. 9, pp. 838-847, doi: 10.1097/MCG.0b013e3181b152a1.

Attached Files
Name Description MIMEType Size Downloads

Title Management of advanced neuroendocrine tumors with hepatic metastasis
Author(s) Khasraw, MustafaORCID iD for Khasraw, Mustafa orcid.org/0000-0003-3249-9849
Gill, Anthony
Harrington, Tim
Pavlakis, Nick
Modlin, Irvin
Journal name Journal of clinical gastroenterology
Volume number 43
Issue number 9
Start page 838
End page 847
Total pages 10
Publisher Lippincott Williams & Wilkins
Place of publication Philadelphia, Pa.
Publication date 2009-10
ISSN 0192-0790
1539-2031
Keyword(s) neuroendocrine tumor
multimodality therapy
TACE
bevacizumab
Sandostatin
fluoropyrimidines
Summary Neuroendocrine tumors (NETs) in general and specifically these gastroenteropancreatic-neuroendocrine tumors often present a considerable diagnostic and therapeutic challenge, especially those that behave in an aggressive fashion. The majority of tumors are diagnosed at a stage that the only curative treatment, radical surgical intervention, is no longer an option and thus long-term therapy with somatostatin analogs is focused on symptom amelioration and in the improvement of quality of life. Although biotherapy is currently the most efficient treatment to achieve palliation, conventional chemotherapy may have some utility in undifferentiated or highly proliferating neuroendocrine carcinomas and pancreatic NETs. Hepatic metastases, depending on size, location, and number may be amenable to surgical resection or radiofrequency ablation. If surgery is not feasible, embolization either alone (bland), in combination with chemotherapeutic agents, or using radioactive microspheres can be used. Peptide receptor targeted radiotherapy using radiolabeled octapeptide analogs (90Yttrium or 177Lutetium-octreotide) may lead to reduction in tumor size, but in most circumstances has a tumor stabilizing effect. A variety of antiangiogenesis and growth factor-targeted agents have been evaluated, but to date, the results have failed to meet our expectations.
Language eng
DOI 10.1097/MCG.0b013e3181b152a1
Field of Research 119999 Medical and Health Sciences not elsewhere classified
Socio Economic Objective 970111 Expanding Knowledge in the Medical and Health Sciences
HERDC Research category C1.1 Refereed article in a scholarly journal
Copyright notice ©2009, Lippincott Williams & Wilkins
Persistent URL http://hdl.handle.net/10536/DRO/DU:30046485

Document type: Journal Article
Collection: School of Medicine
Connect to link resolver
 
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 11 times in TR Web of Science
Scopus Citation Count Cited 10 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 207 Abstract Views, 1 File Downloads  -  Detailed Statistics
Created: Tue, 31 Jul 2012, 12:24:21 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.